Navigation Links
Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission

The pharmaceutical company Starpharma saw an 8% increase in its share, following approval of Vivagel by the FDA, a new formulation, believed to prevent transmission of HIV. // The company even signed a $20 million (US) contract with the US National Institute of Allergy and Infectious Diseases, an integral part of the National Institute of Health.

'There are currently no approved products for the prevention of HIV infection. The FDA recognizes the potential of Vivagel to address this unmet medical need. Vivagel's new drug application will now receive priority review, which has a shorter assessment time. The early review is expected to shorten FDA's approval time significantly', said John Raff, Chief executive of Starpharma.

It is further hoped that the FDA’s initiative to accelerate the approval process would contribute to the development of the company, in the opinion of Jackie Fairley, Chief operating officer, Starpharma.

It was anticipated that the approval and commercial use of the drug would take about 13 months. With this green signal from the FDA, it could be materialized in less than 6 or 7 months according to official reports.

The product is primarily targeted at women, and would help them prevent contracting sexually transmitted diseases such as genital herpes, HIV and so on. The drug, a vaginal formulation has to be topically applied prior to intercourse and would function as a chemical barrier against various infections.

'Vivagel is not a treatment for HIV. The gel is used topically prior to sexual intercourse to prevent the women from becoming infected with HIV, genital herpes and other sexually transmitted diseases', said Dr Fairley.

AIDS is increasingly becoming a global burden, with nearly 40 million people afflicted with the disease worldwide. The number of genital herpes and AIDS/HIV in Australia is estimated to be 3.4 million and 15, 000 respectively. This is of great importan ce as individuals with genital herpes have an increased risk (5 to 7 times greater risk) of contracting the AIDS virus.

A Phase I clinical trial involving the new drug is expected to be launched soon. If the results are satisfactory, the drug would be approved for use in the US, Australia and Europe by the end of 2008.


Related medicine news :

1. Kirin Develops a Cure for Bird Flu
2. Hungary Develops New Bird Flu Vaccine
3. Dutch chemical group Akzo Nobel Develops A New Bird Flu Vaccine
4. Samsung Develops Device to Measure Body Fat
5. India Develops Test for Diagnosis of Deadly Livestock Disease
6. Mouth Cancer Develops In Two Different Ways
7. John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases
8. Researcher Develops Sensor to Detect E.coli
9. Australian Firm Develops Low Glycaemic Sugar to Prevent Diabetes
10. US Company Develops Better Weight Reduction Pill
11. Rhode Island Biotechnology Company Develops Tularemia Vaccine
Post Your Comments:

(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... N.C. , Nov. 25, 2015 ... the planned investment of at least $15.8  Million ... Wilmington, NC . The expansion ... capacity to meet the growing demands of the ... site expansion will provide up to ...
(Date:11/25/2015)... , Nov. 25, 2015  Henry Schein, Inc., the ... to office-based dental, medical and animal health practitioners, will ... the Henry Schein ConnectDental® Pavilion , which brings ... of open solutions designed to help any practice or ... here for a schedule of experts appearing at ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
Breaking Medicine Technology: